Development Outside the Field Sample Clauses

Development Outside the Field. Immunomedics has the right to Develop the Product for use in the Oncology Field. In the event Immunomedics Develops or has Developed the Product for use in the Oncology Field, the following terms shall apply:
View Source
Development Outside the Field. With respect to (a) any Exclusive DARPin and any [***] Compound that Binds [***], in each case that is or may be in the future subject to the restrictions set forth in Section 3.3(a)(ii) or 3.4(b), respectively, and that is commercially exploited by Molecular Partners or its Affiliates for use outside the Field, whether such exploitation is directly by Molecular Partners or indirectly through Affiliates, partners, joint ventures, licensees or other Third Parties, Molecular Partners will use Commercially Reasonable Efforts to prevent the formulation of such Exclusive DARPin or such [***] Compound that Binds [***] from being able to be [***]. Notwithstanding the foregoing, Molecular Partners shall request and use Commercially Reasonable Efforts to include into any agreement entered into after the Effective Date between Molecular Partners (or any of its Affiliates) and such Third Party provisions that obligate such Third Party to agree to comply with the obligations set forth in this Section 3.8 with respect to such Exclusive DARPin or such [***] Compound that Binds [***].
View Source
Development Outside the Field. In the event that either Party develops (hereinafter referred to as the “Developing Party”) the Drug Product or the Drug Substance for an indication(s) outside the Field and obtains new proprietary knowledge or information (whether patentable or not) related to the use of Drug Product or Drug Substance for an indication(s) outside the Field (hereinafter referred to as “Outside-the-Field Know-How”), then the Developing Party shall first notify the other Party of such indication and the Outside-the-Field Know-How, and the Parties shall discuss a license or a collaborative development to such indication and the Outside-the-Field Know-How. In case the Parties fail to enter into such license agreement or a collaborative development for such indication and the Outside-the-Field Know-How as a result of such discussion: (a) the Developing Party shall have the right to commercialize, in all of the countries in the world, such indication; and (b) in case the Developing Party plans to commercialize the Drug Product in a certain country in the territory of the other Party for such indication(s), both Parties shall discuss in good faith on the use of information and data for the NDA in possession of the other Party for such country under terms and conditions to be separately agreed upon, provided, however, that both Parties shall discuss in good faith, if necessary and to the extent permitted by Applicable Laws, on the countermeasures to avoid interference of the other Parties’ licensed Drug Product business in the Field. It is expressly understood that, without a further license grant from DSP, BIOMARIN cannot use the Drug Substance supplied by DSP, the DSP Drug Product Manufacturing Technology, the Drug Substance Manufacturing Know-How, the Informative Know-How, the Drug Substance Patent, or Drug Product Patent in the development of an indication outside the Field. It is further expressly understood that neither Party will have any obligation of disclosure or negotiation pursuant to this Section 3.4 (Development Outside the Field) to the extent that such disclosure or negotiations would violate any obligation of the Developing Party existing on the Effective Date or related to Outside the Field Know-How brought to the attention of the Developing Party by a third party; provided that, in such instance, the Developing Party will use Commercially Reasonable efforts to permit disclosure to the other Party.
View Source

Related to Development Outside the Field

  • Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in ▇▇▇▇▇, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.